251564-45-1

Basic information

• Product Name: Azido-PEG2-CH2CO2tBu
• Synonyms: Azido-PEG2-CH2CO2tBu;8-Azido-3,6-dioxaoctanoic acidtert-butyl ester≥ 95% (GC);N3-AEEA-OtBu;N3-PEG2-CH2COOtBu
• CAS NO: 251564-45-1
• Molecular Formula: C₁₀H₁₉N₃O₄
• Molecular Weight: 245.27556
• Mol File: 251564-45-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Solubility: Soluble in DMSO, DCM, DMF
• CAS DataBase Reference: Azido-PEG2-CH2CO2tBu(CAS DataBase Reference)
• NIST Chemistry Reference: Azido-PEG2-CH2CO2tBu(251564-45-1)
• EPA Substance Registry System: Azido-PEG2-CH2CO2tBu(251564-45-1)

Safety Data

• Hazardous Substances Data: 251564-45-1(Hazardous Substances Data)

Usage

Description

Azido-PEG2-CH2CO2tBu is an azide-containing PEG (polyethylene glycol) molecule with a t-butyl ester. It is a colorless oil that features a reactive azide group, which can form a stable triazole linkage with alkyne, BCN, and DBCO through Click Chemistry. The t-butyl protected carboxyl group in this molecule can be deprotected under acidic conditions, making it a versatile compound for various applications.

Uses

Used in Bioconjugation:
Azido-PEG2-CH2CO2tBu is used as a bioconjugation agent for the covalent attachment of biomolecules to other molecules or surfaces. The azide group's reactivity with alkyne-containing compounds via Click Chemistry allows for the formation of stable and specific bioconjugates, which is crucial in fields such as drug development, diagnostics, and research.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Azido-PEG2-CH2CO2tBu is used as a component in drug delivery systems. The PEGylation of drugs using this molecule can improve their solubility, stability, and circulation time in the body, leading to enhanced therapeutic effects and reduced side effects.
Used in Materials Science:
Azido-PEG2-CH2CO2tBu is used as a building block in the development of functional materials, such as hydrogels and self-assembled nanostructures. The molecule's ability to form stable triazole linkages through Click Chemistry enables the creation of well-defined and biocompatible materials with tailored properties for various applications, including tissue engineering and sensing.
Used in Chemical Synthesis:
In the field of chemical synthesis, Azido-PEG2-CH2CO2tBu serves as an intermediate or a reagent for the synthesis of more complex molecules. The molecule's unique functional groups and reactivity make it a valuable tool for the preparation of novel compounds with potential applications in various industries, such as pharmaceuticals, agrochemicals, and specialty chemicals.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 139115-90-5 2-(2-azidoethoxy)ethanol 
• 149299-82-1 tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate 
• 882518-89-0 tert-butyl 2-[2-[2-(p-tolylsulfonyloxy)ethoxy]ethoxy]acetate 

Downstream Products

• 1122484-77-8 [2-(2-aminoethoxy)ethoxy]acetic acid tert-butyl ester 

Relevant articles and documents

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative

Bromodomain-containing protein 4 (BRD4) plays a crucial role in the epigenetic regulation of gene transcription and some BRD4 inhibitors have been advanced to clinical trials. Nevertheless, the clinical application of BRD4 inhibitors could be limited by drug resistance. As an alternative strategy, the emerging Proteolysis Targeting Chimeras (PROTACs) technology has the potential to overcome the drug resistance of traditional small-molecule drugs. Based on PROTACs approaches, several BRD4 degraders were developed and have been proved to degrade BRD4 protein and inhibit tumor growth. Herein, we present the design, synthesis, and biological evaluation of pyrrolopyridone derivative-based BRD4 degraders. Four synthesized compounds displayed comparative potence against BRD4 BD1 with IC50 at low nanomolar concentrations. Anti-proliferative activity of 32a against BxPC3 cell line (IC50 = 0.165 μM) was improved by about 7-fold as compared to the BRD4 inhibitor ABBV-075. Furthermore, degrader 32a potently induced the degradation of BRD4 and inhibited the expression of c-Myc in BxPC3 cell line in a time-dependent manner. The exploration of intracellular antitumor mechanism showed 32a induced cell cycle arrest and apoptosis effectively. All the results demonstrated that compound 32a could be considered as a potential BRD4 degrader for further investigation.

Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study

The synthesis of a new class of template-assembled oligomannose clusters as the mimics of the epitope of the HIV-neutralizing antibody 2G12 is described. The novel oligomannose clusters were successfully assembled on a cyclic decapeptide template using th